n.a. (SNTS)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 67.14M
Div & Yield N.A. (N.A)
Santarus To Present At September Investment Conferences

Santarus To Present At September Investment Conferences

Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T.

Santarus Inc. (SNTS): Today's Featured Health Care Laggard

Santarus Inc. (SNTS): Today's Featured Health Care Laggard

Santarus was a leading decliner within the health care sector, falling $1.08 (-4.3%) to $24.15 on average volume

First Week Of October 19th Options Trading For Santarus (SNTS)

First Week Of October 19th Options Trading For Santarus (SNTS)

Investors in Santarus Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SNTS options chain for the new October 19th contracts and identified one put and one call contract of particular interest.

3 Big Biotech Stocks Rising on Big Volume

3 Big Biotech Stocks Rising on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Santarus Reports Second Quarter 2013 Financial Results

Santarus Reports Second Quarter 2013 Financial Results

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the quarter ended June 30, 2013.

Santarus Inc. (SNTS): Today's Featured Drugs Laggard

Santarus Inc. (SNTS): Today's Featured Drugs Laggard

Santarus was a leading decliner within the drugs industry, falling $0.94 (-3.9%) to $23.20 on average volume

External Catalysts Will Predominate

This week a sustained trend in either direction may be hard to find, although the S&P 500 has a good chance to hit 1700 at least once.

Santarus To Hold Second Quarter 2013 Financial Results Conference Call On August 6

Santarus To Hold Second Quarter 2013 Financial Results Conference Call On August 6

Santarus, Inc. (NASDAQ: SNTS) today announced that it will release second quarter 2013 financial results after market close on Tuesday, August 6, 2013.

Santarus Completes Patient Enrollment In CONTRIBUTE Study With UCERIS (budesonide) As Add-on Treatment To 5-ASA Drugs

Santarus Completes Patient Enrollment In CONTRIBUTE Study With UCERIS (budesonide) As Add-on Treatment To 5-ASA Drugs

Santarus, Inc. (NASDAQ: SNTS) today announced the completion of enrollment in the CONTRIBUTE clinical study designed to evaluate the incremental benefit of adding UCERIS ® (budesonide) extended release 9 mg ...

Santarus Stock Hits New 52-Week High (SNTS)

Santarus Stock Hits New 52-Week High (SNTS)

Santarus (Nasdaq:SNTS) hit a new 52-week high Thursday as it is currently trading at $24.46, above its previous 52-week high of $24.43 with 1.4 million shares traded as of 2:05 p.m. ET. Average volume has been 1.4 million shares over the past 30 days.

Insider Trading Alert - VistaPrint And 3 Others Traded By Insiders

Insider Trading Alert - VistaPrint And 3 Others Traded By Insiders

Stocks with insider trader activity include VPRT, DISCA, PAYX and SNTS

5 Stocks Spiking on Unusual Volume

5 Stocks Spiking on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Santarus To Present At JMP Securities Healthcare Conference

Santarus To Present At JMP Securities Healthcare Conference

Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T.

Santarus And Pharming Announce Poster Presentation Of Pivotal Clinical Data For RUCONEST (Recombinant Human C1 Esterase Inhibitor)

Santarus And Pharming Announce Poster Presentation Of Pivotal Clinical Data For RUCONEST (Recombinant Human C1 Esterase Inhibitor)

Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) announced that new data from a pivotal Phase III clinical study with RUCONEST ® (recombinant human C1 esterase inhibitor) for the...

Santarus And VeroScience Announce CYCLOSET (bromocriptine Mesylate) Data Presentations At The American Diabetes Association Meeting

Santarus And VeroScience Announce CYCLOSET (bromocriptine Mesylate) Data Presentations At The American Diabetes Association Meeting

Santarus, Inc. (NASDAQ: SNTS) and VeroScience, LLC today announced that clinical data on CYCLOSET ® (bromocriptine mesylate) will be featured in two poster presentations at the 73 rd Scientific Sessions of...

Santarus And Pharming Announce FDA Acceptance For Review Of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application

Santarus And Pharming Announce FDA Acceptance For Review Of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application

Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) today announced that the U.

Santarus President & CEO Gerald Proehl Honored As San Diego Ernst & Young Entrepreneur Of The Year 2013 In Life Sciences

Santarus President & CEO Gerald Proehl Honored As San Diego Ernst & Young Entrepreneur Of The Year 2013 In Life Sciences

Santarus, Inc. (NASDAQ:SNTS) today announced that Gerald T.

'Mad Money' Lightning Round: Still Waiting on McDonald's

'Mad Money' Lightning Round: Still Waiting on McDonald's

Cramer likes Quintiles Transnational and Dover Corp. but thinks Melco PBL Entertainment has hit a plateau.

Cramer's 'Mad Money' Recap: The Rich Are Different

Cramer's 'Mad Money' Recap: The Rich Are Different

They are clearly spending a lot more than the middle class, if the results of Cramer's 'Gatsby Index' are any indication.

Santarus Announces Publication In Gut Of Results From UCERIS (budesonide) European Pivotal Clinical Study

Santarus Announces Publication In Gut Of Results From UCERIS (budesonide) European Pivotal Clinical Study

Santarus, Inc. (NASDAQ: SNTS) today announced that results from its CORE II clinical study, one of two of the company’s pivotal Phase III clinical studies with UCERIS ™ (budesonide) extended release...

Santarus And VeroScience Announce Publication Of AACE Expert Panel Recommendations For CYCLOSET® (bromocriptine Mesylate) For The Management Of Type 2 Diabetes

Santarus And VeroScience Announce Publication Of AACE Expert Panel Recommendations For CYCLOSET® (bromocriptine Mesylate) For The Management Of Type 2 Diabetes

Santarus, Inc. (NASDAQ: SNTS) and VeroScience, LLC today announced publication of a review article and recommendations of an American Association of Clinical Endocrinologists (AACE) expert panel on the role of ...

Dow Closes at Record High

Dow Closes at Record High

Major U.S. stock averages saw strong momentum Tuesday, with the Dow recording an all-time closing high.

Santarus Reports Fourth Quarter And Full Year 2012 Financial Results

Santarus Reports Fourth Quarter And Full Year 2012 Financial Results

Santarus, Inc. (NASDAQ: SNTS), today reported financial and operating results for the quarter and year ended December 31, 2012.

Santarus To Present At March Investment Conferences

Santarus To Present At March Investment Conferences

Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T.

Santarus To Hold Fourth Quarter And Full Year 2012 Financial Results Conference Call On March 4

Santarus To Hold Fourth Quarter And Full Year 2012 Financial Results Conference Call On March 4

Santarus, Inc. (NASDAQ: SNTS) today announced that it will release fourth quarter 2012 financial results after market close on Monday, March 4, 2013.

Santarus Announces Commercial Launch Of UCERIS (budesonide) Extended Release Tablets

Santarus Announces Commercial Launch Of UCERIS (budesonide) Extended Release Tablets

Santarus, Inc. (NASDAQ: SNTS) announced today the U.

Santarus To Present At Leerink Swann Global Healthcare Conference

Santarus To Present At Leerink Swann Global Healthcare Conference

Santarus, Inc. (NASDAQ: SNTS) today announced that Debra P.

Santarus And VeroScience Announce Publication Of Positive Data From Pivotal CYCLOSET® (bromocriptine Mesylate) Efficacy Study

Santarus And VeroScience Announce Publication Of Positive Data From Pivotal CYCLOSET® (bromocriptine Mesylate) Efficacy Study

Santarus, Inc. (NASDAQ: SNTS) and VeroScience, LLC today announced publication of positive data from a double-blind, placebo-controlled, multi-center pivotal study with CYCLOSET ® (bromocriptine mesylate) ...

Cramer's 'Mad Money' Recap: The Bullish Facts

Cramer's 'Mad Money' Recap: The Bullish Facts

It's hard to be a bear in this market over the long run, Cramer said.